News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Canadian retail sales rose 1.0% in May, with a 0.4% advance estimate for June, implying continued consumer demand.
  • Intuitive Surgical unveiled an AI framework and demonstrated remote telesurgery, highlighting AI-driven expansion in robotic-assisted procedures.
  • Morgan Stanley added Broadcom and exited Eaton, shifting a portfolio toward AI-semiconductor and software exposure.
  • A bipartisan bill would give DHS power to order shutdowns of AI models deemed dangerous, raising regulatory risk for developers.
  • Yelp shares jumped after reports the company will license reviews and photos to OpenAI, boosting monetization ahead of earnings.
  • Agilent secured EU clearance for its PD-L1 ovarian-cancer diagnostic, enabling companion testing linked to pembrolizumab treatment.
  • Wheat futures wobbled as reported attacks on Black Sea grain shipping raised supply concerns, offset by profit-taking.

Latest Articles

Alignment Healthcare Shows How Earlier, Coordinated Care Leads to Better Health and Fewer Emergencies in 2025 Impact Report

Alignment Healthcare Shows How Earlier, Coordinated Care Leads to Better Health and Fewer Emergencies in 2025 Impact Report

Alignment Healthcare released its 2025 Impact Report showcasing its effective care model that leads to healthier members by providing earlier, coordinated care. The company demonstrated substantial reductions in emergency room visits, inpatient admissions, skilled nursing facility admissions, and 30-day hospital readmission rates compared to Medica…

ProKidney Appoints Kenneth Locke as Chief Technical Officer

ProKidney Appoints Kenneth Locke as Chief Technical Officer

ProKidney Corp., a Nasdaq-listed late clinical-stage cell therapy company focused on chronic kidney disease, appoints Kenneth Locke as Chief Technical Officer to lead technical operations as it advances its Phase 3 REGEN-006 trial and prepares for potential commercialization of its autologous cell therapy, rilparencel.

Plug Power Strengthens Liquidity Through $44 Million Federal ITC Transfer for St. Gabriel Hydrogen Facility

Plug Power Strengthens Liquidity Through $44 Million Federal ITC Transfer for St. Gabriel Hydrogen Facility

Plug Power announced the successful sale of a $39.2 million federal investment tax credit related to its St. Gabriel, Louisiana hydrogen liquefaction plant. This transaction enhances Plug Power's liquidity and supports its strategic financial management and expansion of its hydrogen infrastructure in the United States. The St. Gabriel facility, one…

Polar Power Highlights Sharply Improved First Quarter 2026 Performance and Recent Operational Progress

Polar Power Highlights Sharply Improved First Quarter 2026 Performance and Recent Operational Progress

Polar Power, Inc. released its Q1 2026 financial results showing a major improvement in gross margin to 65.7%, a narrowed net loss by 86%, and reduced operating expenses by 22% compared to Q1 2025. The company also secured a lower rent agreement, improved stockholders' equity, and expanded its sales backlog largely driven by international telecom c…

SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing

SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing

SpyGlass Pharma has appointed Mike Pinder as Vice President of Marketing to lead commercial efforts for its late-stage BIM-IOL System, currently in Phase 3 trials for glaucoma and cataract treatment. Pinder brings extensive ophthalmology commercial launch experience, positioning the company for potential successful commercialization upon FDA approv…

Comscore’s Q1 2026 AI Intelligence Report Shows Scale of Claude’s Breakout Growth as AI Continues to Influence Search, Discovery and Consumer Decisions

Comscore’s Q1 2026 AI Intelligence Report Shows Scale of Claude’s Breakout Growth as AI Continues to Influence Search, Discovery and Consumer Decisions

Comscore's Q1 2026 AI Intelligence Report reveals significant growth in AI assistant platforms, particularly Anthropic's Claude, which saw an 1,858% rise in desktop conversations. ChatGPT remains the leader with 55% year-over-year growth in desktop conversations. The report highlights the increasing integration of AI into search and consumer decisi…

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

UroGen Pharma Ltd. announced a settlement with Teva Pharmaceuticals resolving patent litigation concerning Teva's generic version of JELMYTO® (mitomycin) for pyelocalyceal solution. The agreement grants Teva a non-exclusive license to market the generic after September 15, 2030, preserving nearly all of UroGen's patent exclusivity. The resolution a…

ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026

ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026

Enlivex Ltd., a Nasdaq-listed quality longevity company, announced its Gold Sponsorship of the Proof of Talk 2026 summit in Paris, featuring a presentation on its unique combination of clinical-stage longevity therapeutics development and a prediction markets treasury strategy anchored in the Rain protocol. This innovative approach targets aging-re…

House of Doge Celebrates Winning The Milano Hockey Club Franchise APPROVAL and Admission to the ICE Hockey League for the 2026/27 Season

House of Doge Celebrates Winning The Milano Hockey Club Franchise APPROVAL and Admission to the ICE Hockey League for the 2026/27 Season

House of Doge, in partnership with Brag House Holdings (NASDAQ: TBH), celebrates the admission of Milano Hockey Club to the ICE Hockey League starting in the 2026/27 season. This marks the return of top-level professional hockey to Milan, supported by a new arena set to become a hub for ice sports. The investment aligns with House of Doge's multi-c…

FLYTE ACTIVATES HIGH-FREQUENCY BELMONT STAKES FLIGHT PROGRAM, DEPLOYING FLEET TO CAPTURE TRIPLE CROWN DEMAND

FLYTE ACTIVATES HIGH-FREQUENCY BELMONT STAKES FLIGHT PROGRAM, DEPLOYING FLEET TO CAPTURE TRIPLE CROWN DEMAND

Catheter Precision's regional air mobility subsidiary, Flyte, announces deployment of Cirrus Vision Jets to key Northeast routes ahead of the Belmont Stakes horse race. This strategic move targets high-net-worth and corporate travelers amid expected travel congestion, showcasing Flyte's scalable model for short-haul private aviation and supporting …

VCI Global’s V Gallant Signs Definitive Agreement to Acquire Rights Platform Covering 241,000 Hectares of Indonesian Forestry Assets to Accelerate AI, Carbon Credit and RWA Ecosystem Strategy

VCI Global’s V Gallant Signs Definitive Agreement to Acquire Rights Platform Covering 241,000 Hectares of Indonesian Forestry Assets to Accelerate AI, Carbon Credit and RWA Ecosystem Strategy

VCI Global Limited (NASDAQ: VCIG), through its subsidiary V Gallant Limited, has entered into a definitive agreement to acquire a controlling stake in PT Fine Carbon Credit Indonesia, a carbon asset platform managing approximately 241,000 hectares of forestry assets in Indonesia. This acquisition aligns with VCI Global’s strategy to integrate AI in…

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Disc Medicine presented updated Phase 2 RALLY-MF trial data showing that DISC-0974 substantially reduces hepcidin and increases iron levels, leading to meaningful and durable anemia improvements across all patient subgroups with myelofibrosis (MF), including those receiving JAK inhibitor therapy. The treatment improved hemoglobin levels, reduced tr…

zSpace Appoints VR Expert as Master Reseller for Europe, Expanding Access to Immersive Learning Across the Region

zSpace Appoints VR Expert as Master Reseller for Europe, Expanding Access to Immersive Learning Across the Region

zSpace, Inc., a US-based AI-powered AR/VR education technology provider, announced a master reseller agreement with VR Expert, a leading European distributor. This partnership will expand zSpace's immersive learning solutions throughout Europe, enhancing adoption in career and technical education, STEM, and workforce development sectors across scho…

BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform

BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform

BullFrog AI Holdings, Inc., a Nasdaq-listed company leveraging AI and machine learning for drug discovery, announces key appointments in its commercial leadership team. These new executives bring extensive experience in global sales, biotech corporate strategy, and scientific operations, aiming to accelerate the company's commercial growth strategy…

Teads Announces Audience API Integration with Havas Media Network

Teads Announces Audience API Integration with Havas Media Network

Teads announced the integration of its Audience Planning API into Havas Media Network's Converged.AI platform, enabling media planners to activate targeted audiences seamlessly and efficiently across Teads' premium global network. This first agency-platform integration enhances accuracy, consistency, and speed of audience activation while supportin…

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Cingulate Inc. received a Complete Response Letter from the FDA concerning its NDA for CTx-1301, an ADHD treatment. The FDA's concerns center around Chemistry, Manufacturing, and Controls (CMC) data, with no current clinical safety or efficacy issues noted. The company plans to quickly address the FDA's requests and resubmit, supported by nearly $3…